Bone Biologics Corp Stock Probability of Future Stock Price Finishing Over 8.26

BBLG Stock  USD 1.49  0.04  2.61%   
Bone Biologics' future price is the expected price of Bone Biologics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Bone Biologics Corp performance during a given time horizon utilizing its historical volatility. Check out Bone Biologics Backtesting, Bone Biologics Valuation, Bone Biologics Correlation, Bone Biologics Hype Analysis, Bone Biologics Volatility, Bone Biologics History as well as Bone Biologics Performance.
  
At this time, Bone Biologics' Price Fair Value is most likely to increase significantly in the upcoming years. Please specify Bone Biologics' target price for which you would like Bone Biologics odds to be computed.

Bone Biologics Target Price Odds to finish over 8.26

The tendency of Bone Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 8.26  or more in 90 days
 1.49 90 days 8.26 
close to zero percent
Based on a normal probability distribution, the odds of Bone Biologics to move over $ 8.26  or more in 90 days from now is close to zero percent (This Bone Biologics Corp probability density function shows the probability of Bone Stock to fall within a particular range of prices over 90 days) . Probability of Bone Biologics Corp price to stay between its current price of $ 1.49  and $ 8.26  at the end of the 90-day period is about 85.86 .
Given the investment horizon of 90 days Bone Biologics has a beta of 0.82 suggesting as returns on the market go up, Bone Biologics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Bone Biologics Corp will be expected to be much smaller as well. Additionally Bone Biologics Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
   Bone Biologics Price Density   
       Price  

Predictive Modules for Bone Biologics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bone Biologics Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bone Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.071.417.15
Details
Intrinsic
Valuation
LowRealHigh
1.3410.5316.27
Details
Naive
Forecast
LowNextHigh
0.031.727.46
Details
1 Analysts
Consensus
LowTargetHigh
34.3537.7541.90
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bone Biologics. Your research has to be compared to or analyzed against Bone Biologics' peers to derive any actionable benefits. When done correctly, Bone Biologics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Bone Biologics Corp.

Bone Biologics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Bone Biologics is not an exception. The market had few large corrections towards the Bone Biologics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bone Biologics Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bone Biologics within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.52
β
Beta against NYSE Composite0.82
σ
Overall volatility
0.27
Ir
Information ratio -0.09

Bone Biologics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bone Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bone Biologics Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Bone Biologics Corp generated a negative expected return over the last 90 days
Bone Biologics Corp has high historical volatility and very poor performance
Bone Biologics Corp may become a speculative penny stock
Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0.
Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Bone Biologics Corp has a frail financial position based on the latest SEC disclosures
Latest headline from benzinga.com: Bone Biologics Executives to be Interviewed in a CEO Chat by Zacks Small-Cap Research Analyst on June 20th

Bone Biologics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bone Stock often depends not only on the future outlook of the current and potential Bone Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bone Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding263.1 K
Cash And Short Term InvestmentsM

Bone Biologics Technical Analysis

Bone Biologics' future price can be derived by breaking down and analyzing its technical indicators over time. Bone Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bone Biologics Corp. In general, you should focus on analyzing Bone Stock price patterns and their correlations with different microeconomic environments and drivers.

Bone Biologics Predictive Forecast Models

Bone Biologics' time-series forecasting models is one of many Bone Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bone Biologics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Bone Biologics Corp

Checking the ongoing alerts about Bone Biologics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bone Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Bone Biologics Corp generated a negative expected return over the last 90 days
Bone Biologics Corp has high historical volatility and very poor performance
Bone Biologics Corp may become a speculative penny stock
Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0.
Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Bone Biologics Corp has a frail financial position based on the latest SEC disclosures
Latest headline from benzinga.com: Bone Biologics Executives to be Interviewed in a CEO Chat by Zacks Small-Cap Research Analyst on June 20th

Additional Information and Resources on Investing in Bone Stock

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
19.88
Return On Assets
(0.85)
Return On Equity
(1.89)
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.